Home > Insider Trading > Filing (0000899243-20-018812)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	Biological Products, (No Disgnostic Substances) (2836)	473173478

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1682017	Rodger Novak	C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139	President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2020-07-07	5,586	$1.81	653,593	No	4	M	Direct
Common Shares	Acquisiton	2020-07-07	19,414	$14.00	673,007	No	4	M	Direct
Common Shares	Disposition	2020-07-07	25,000	$90.00	648,007	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2020-07-07	5,586	$0.00	5,586	$1.81
Common Shares	Stock Option (Right to Buy)	Disposition	2020-07-07	19,414	$0.00	19,414	$14.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2025-09-10	No	4	M	Direct
140,826		2026-10-18	No	4	M	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vesting in 31 equal monthly installments thereafter.
This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.